SOURCE: Leerink Swann & Co.

October 13, 2005 06:00 ET

Leerink Swann & Company Initiates Coverage of MannKind Corporation (NASDAQ: MNKD)

BOSTON, MA -- (MARKET WIRE) -- October 13, 2005 -- Yesterday after the close, Senior Biotechnology Analyst, William Tanner, Ph.D., initiated coverage of MannKind Corporation (NASDAQ: MNKD) with an Outperform rating. His investment rating is based on his belief that MannKind's Technosphere, a potential best-in-class inhaled insulin product, positions it well for partnering opportunities.

About MannKind Corporation

MannKind Corporation (NASDAQ: MNKD) focuses on the discovery, development and commercialization of therapeutic products for diseases such as diabetes and cancer. Its lead product, the Technosphere® Insulin System, is currently in phase 3 clinical trials in the U.S. and Europe to study its safety and efficacy in the treatment of diabetes. MannKind is headquartered in Valencia, California.

About Leerink Swann & Company

Leerink Swann & Company is an investment banking firm that provides healthcare equity research, corporate finance, and asset management services for institutional and high-net-worth clients. Leerink Swann & Company was voted the Best Firm in Biotechnology, Medical Supplies and Devices, Pharmaceuticals/Major and Pharmaceuticals/Specialty in the December 2004 Institutional Investor poll ranking the best boutique and regional firms by sector. Through its consulting affiliate, MEDACorp, Leerink Swann & Company provides biomedical-consulting services to Life Sciences companies and to the institutional investment community. MEDACorp includes thousands of biomedical professionals and practicing physicians. Leerink Swann & Company is a member NASD/SIPC.

Contact Information

  • Contact:
    John I. Fitzgerald
    Leerink Swann & Company
    (617) 918-4564
    www.leerink.com